Clinical Trials Logo

Clinical Trial Summary

Specific aim: To establish the proof of principle that treatment of "high breast cancer risk" women with recombinant human chorionic gonadotropin (r-hCG) will change their breast epithelium's high risk genomic profile to one similar to that identified in women with a history of early full first term pregnancy.

Clinical Trial Description

This study is based on the investigators preclinical data that have demonstrated that r-hCG exerts a mammary cancer preventive effect that is mediated by the induction of gland differentiation, which results in permanent changes in the genomic signature of this organ. This exploratory study will evaluate the genomic profile of breast epithelial cells obtained from random periareolar fine needle aspiration (RPFNA) specimens performed in high risk women treated for 90 days (an extra 4 weeks in a subgroup) with r-hCG. This knowledge will serve as the basis for establishing a novel genomic biomarker that will serve as a surrogate endpoint in future preventive clinical trials.

The objective of the proposed study is to characterize the genomic profile of breast epithelial cells obtained from 35 asymptomatic high breast cancer risk nulliparous premenopausal women carriers of BRCA1 and BRCA2 deleterious mutations. Gene expression measurements and benign breast tissue specimens will be obtained at baseline (time 0), after treatment with r-hCG at 90 days (time 1), at 270 days from baseline (time 2) and (in a subgroup) at 60 weeks (+/- 4 weeks).

The primary objective of the study is to compare the gene expression profiles of these women across the three (or four) time points and identify differentially expressed genes. The investigator is interested in comparing the expression profiles between all pairs of time points as well as across time. The comparison of profiles before and after treatment with r-hCG, both at 90 and 270 days are of particular interest. The women will receive 3x/week injections of 250 microgram r-hCG for a total of 12 weeks (an extra 4 weeks in a subgroup). Core Needle Biopsies specimens will be primarily utilized for analysis of genomic expression by cDNA microarray. In addition, a series of surrogate intermediate markers such as cytomorphologic evaluation and cell proliferation index will be analyzed. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03495609
Study type Interventional
Source University Hospital, Ghent
Contact Herman Depypere, Prof.
Phone 0032 9 332 37 76
Status Recruiting
Phase Phase 4
Start date February 17, 2016
Completion date July 2021

See also
  Status Clinical Trial Phase
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Not yet recruiting NCT03685331 - Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer Phase 1
Recruiting NCT02957981 - The Genetic Education for Men Trial: Web-Based Education vs. Standard Care N/A
Recruiting NCT03428399 - Depression and Body Image Distress Following Mastectomy With Reconstruction N/A
Active, not recruiting NCT02974842 - Pre-Salpingo-Oophorectomy Pilot Study of MAKO 7 Device Performance
Recruiting NCT03351803 - BRCA Founder OutReach (BFOR) Study
Recruiting NCT03475979 - Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing
Recruiting NCT03684733 - Magnetic Resonance Breast Tissue Characterisation to Improve Risk Stratification for Breast Cancer
Recruiting NCT01630226 - Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland Phase 2
Recruiting NCT03570125 - BRCA Main Home Nutritional Intervention-random Study N/A
Terminated NCT00700778 - Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations N/A
Completed NCT01611727 - Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients Phase 2
Not yet recruiting NCT03544983 - Genetic Education in BRCA Families N/A
Not yet recruiting NCT03835793 - Health After eaRly Menopause Due to Oophorectomy
Active, not recruiting NCT01608074 - Radical Fimbriectomy for Young BRCA Mutation Carriers N/A
Recruiting NCT03470402 - Decision Support for BRCA Testing in Ethnically Diverse Women N/A
Recruiting NCT03066856 - Dietary Intervention and BRCA Penetrance N/A
Recruiting NCT03702309 - Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Completed NCT01591746 - Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction Phase 3
Withdrawn NCT01409226 - 3.0 Tesla Magnetic Resonance Imaging for Breast Cancer Detection in High Risk Women N/A